Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Aphios Announces Presentation of Phase II/III Clinical Trial Data on Zindol® for Cancer Chemotherapy Induced Nausea

Abstract:
Aphios Corporation today announced that the results of a Phase II/III clinical trial of Zindol® for cancer chemotherapy induced nausea will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from May 29 to June 02, 2009 in Orlando, FL. Zindol® is an enhanced ginger product.

Aphios Announces Presentation of Phase II/III Clinical Trial Data on Zindol® for Cancer Chemotherapy Induced Nausea

Woburn, MA | Posted on May 26th, 2009

Despite the widespread use of the 5-HT3 receptor antagonist antiemetics, post-chemotherapy nausea and vomiting continue to be reported by up to 70% of patients receiving chemotherapy. Furthermore, these antiemetics have been associated with significant adverse effects, such as sedation, extra-pyramidal side effects and hypotension (associated with dopamine antagonists), as well as headache, diarrhea or constipation. A desirable attribute in any substitute or additional antiemetic medication is both efficacy and the absence of clinically significant adverse effects.

Zindol® is an enhanced ginger product that is standardized by the bioactive constituents of ginger, gingerols and shogaols. Aphios' scientists and engineers utilized a proprietary polarity-guided SuperFluids™ CXF fractionation technology to establish conditions for the isolation of the active ingredients of Zindol®. The technology was then scaled-up for producing large quantities of the active ingredients utilizing patented SuperFluids™ CXP manufacturing technologies. The enhanced ginger concentrate was then formulated to achieve a specific concentration of ginger bioactives with all-natural liquid excipients designed to maximize stability and bioavailability of bioactive constituents, and encapsulated in gel capsules (LiCaps®) by Capsugel, Inc., a Pfizer subsidiary.

Researchers at the University of Rochester Medical School conducted a multi-site, Phase II/III randomized, placebo-controlled, double-blind clinical trial to assess the efficacy of Zindol® (ginger capsules) for chemotherapy-related nausea in 644 cancer patients. Cancer patients who experienced nausea were randomized into four arms: placebo and 3 dose-escalation arms taking ginger capsules equivalent to 0.5, 1.0 and 1.5 grams ginger. All patients received 5-HT3 receptor antagonist antiemetics on Day 1 of all cycles. Data from the clinical trial indicates that all ginger doses significantly reduced nausea with the middle and lowest doses giving the best results. Ginger caused no side effects in this study, but patients should consult with their physicians before use.

The results of the clinical trial study entitled "Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients," will be orally presented and discussed on Saturday, May 30, 2009 from 1:00 to 4:00 p.m. in the Patient and Survivor Care session (Level 2, West Hall F5) of ASCO, Orlando, FL.

####

About Aphios
Aphios Corporation is a biotechnology company that is developing enabling technology platforms including nanotechnology drug delivery platforms such as phospholipid nanosomes, biodegradable polymer nanospheres, and protein and crystal nanoparticles for the improved delivery and targeting of poorly water-soluble anticancer drugs, therapeutic proteins and siRNA molecules, as well as enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and CNS disorders.

For more information, please click here

Contacts:
Aphios Corporation
Trevor P. Castor, Ph.D., CEO, (001) 781-932-6933

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Leti Presents Advances in Propagation Modeling and Antenna Design for mmWave Spectrum: Paper Is One of 15 that Leti Presented at European Conference on Antennas and Propagation March 19-24 March 23rd, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Nanomedicine

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Nanocages for gold particles: what is happening inside? March 16th, 2017

Announcements

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Nanobiotechnology

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Nanocages for gold particles: what is happening inside? March 16th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project